
News|Articles|May 19, 2011
Pfizer kidney cancer drug effective in phase III study
NEW YORK (Reuters) - A drug from Pfizer Inc delayed progression of advanced kidney cancer by nearly seven months, and by two months longer than a commonly used medicine, in previously treated patients, according to data from a late stage clinical trial.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Cobenfy in Practice: Hope, Hurdles, and the Next Chapter in Schizophrenia Care
2
Making Sense of the Eye Pain-Headache Connection | AAO 2025
3
What’s New in the Diagnosis and Treatment of Headaches That Ophthalmologists Should Know About? | AAO 2025
4
AI in Ophthalmology: The Key to the Present Success Includes a CPT Code. The Future? Agentic AI That Doesn’t Wait To Be Told What To Do | AAO 2025
5